ABSTRACT
Background: To describe a case of bilateral transient myopia with shallow anterior chamber, ciliochoroidal detachment and uveitis in both eyes induced by indapamide intake following SARS-CoV-2 infection. Case presentation: A 37-year-old man with COVID-19 was referred to our department for bilateral visual blurring. He had been treated with ibuprofen for fever and indapamide to treat the uncontrolled blood pressure. After indapamide intake for four days, he started complaining of bilateral visual blurring. On ocular examination, the uncorrected visual acuity was 20/400 OD and 20/400 OS. Slit-lamp examination revealed shallow anterior chamber. In the patient’s subsequent visit on the next day, he complained of pain and redness in both eyes from the previous night. On ocular examination, the IOP decreased significantly compared to the previous day, 11 mmHg and 12 mmHg in OD and OS respectively. Slit-lamp examination revealed conjunctival injection and inflammatory cells (2+) in the shallow anterior chamber of both eyes. Ultrasound biomicroscopy revealed ciliary body detachment, and B-scan ultrasound showed peripheral shallow choroidal detachment in both eyes. Stopping the indapamide and treatment with oral prednisolone, topical tobramycin dexamethasone and tropicamide phenylephrine eye drops resulted in rapid recovery of the signs and symptoms after 3 days. Conclusions: Indapamide intake can induce bilateral shallow anterior chamber, ciliochoroidal detachment in both eyes, and the preexisting hyperinflammation induced by COVID-19 might increase the susceptibility; drug usage and SARS-CoV-2 infection might commonly contribute to the uveitis. Timely diagnosis and treatment can result in good prognosis.